FDA approves antidepressant nasal spray
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment-resistant depression.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may help those suffering from depression.
Many people with depression and anxiety in the U.S. could benefit from medication but do not receive any treatment, psychiatrist Mark Olfson told Newsweek.